Cargando…
Concomitant drugs associated with increased mortality for MDMA users reported in a drug safety surveillance database
3,4-Methylenedioxymethamphetamine (MDMA) is currently being evaluated by the Food and Drug Administration (FDA) for the treatment of post-traumatic stress disorder (PTSD). If MDMA is FDA-approved it will be important to understand what medications may pose a risk of drug–drug interactions. The goal...
Autores principales: | Cohen, Isaac V., Makunts, Tigran, Abagyan, Ruben, Thomas, Kelan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7966744/ https://www.ncbi.nlm.nih.gov/pubmed/33727616 http://dx.doi.org/10.1038/s41598-021-85389-x |
Ejemplares similares
-
Reported Cases of Serotonin Syndrome in MDMA Users in FAERS Database
por: Makunts, Tigran, et al.
Publicado: (2022) -
Concomitant medications associated with ischemic, hypertensive, and arrhythmic events in MDMA users in FDA adverse event reporting system
por: Makunts, Tigran, et al.
Publicado: (2023) -
Cardiac adverse events associated with chloroquine and hydroxychloroquine exposure in 20 years of drug safety surveillance reports
por: Cohen, Isaac V., et al.
Publicado: (2020) -
Common osteoporosis drug associated with increased rates of depression and anxiety
por: Keshishi, Dro, et al.
Publicado: (2021) -
Analysis of postmarketing safety data for proton-pump inhibitors reveals increased propensity for renal injury, electrolyte abnormalities, and nephrolithiasis
por: Makunts, Tigran, et al.
Publicado: (2019)